All In Biotech

Drug Trial Radar · NCT00075829

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)

Last checked: Nov 20, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 710 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

710

Actual

Start

Dec 2003

Primary completion

Jun 2012

Study completion Mar 2013

Sponsor

Sponsor type
NIH
Collaborators
Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program
First posted
Jan 13, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.

Conditions

  • Multiple Myeloma

Interventions

  • One Autologous TransplantProcedure

    Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.

  • Non-Myeloablative Allogeneic TransplantProcedure

    Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.

  • Second Autologous TransplantProcedure

    Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.

  • ThalidomideDrug

    Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.

  • DexamethasoneDrug

    Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.

  • ObservationBehavioral

    One year of observation post-transplants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Year 3

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • City of Hope Samaritan

    Phoenix, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • Scripps Clinic/Green Hospital

    La Jolla, California

  • UCSD Medical Center

    La Jolla, California

  • Stanford Hospital and Clinics

    Stanford, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • University of Florida College of Medicine (Shands)

    Gainesville, Florida

  • Emory University

    Atlanta, Georgia

  • BMT Group of Georgia/Northside Hospital

    Atlanta, Georgia

  • Loyola University

    Maywood, Illinois

  • IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health

    Indianapolis, Indiana

  • Wichita CCOP

    Wichita, Kansas

  • Tufts - New England Medical Center

    Boston, Massachusetts

  • DFCI/Brigham & Women's

    Boston, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Jewish Hospital BMT Program

    Cincinnati, Ohio

  • University Hospitals of Cleveland/Case Western

    Cleveland, Ohio

  • University of Oklahoma Medical Center

    Oklahoma City, Oklahoma

  • Oregon Health Sciences University (A)

    Portland, Oregon

  • University of Pennsylvania Cancer Center

    Philadelphia, Pennsylvania

  • Fox Chase - Temple University - BMT Program

    Philadelphia, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • Baylor College of Medicine/The Methodist Hospital

    Houston, Texas

  • University of Texas/MD Anderson Cancer Research Center

    Houston, Texas

  • Texas Transplant Institute

    San Antonio, Texas

  • Utah BMT/Univ of Utah Med School

    Salt Lake City, Utah

  • Virginia Commonwealth University MCV Hospitals

    Richmond, Virginia

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • University of Wisconsin Hospitals & Clinics

    Madison, Wisconsin

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.